Harrow Health (HROW) Misses Q4 EPS by 22c, provides guidance

Harrow Health (NASDAQ: HROW) reported Q4 EPS of $0.17, $0.22 worse than the analyst estimate of $0.39. Revenue for the quarter came in at $89.1 million versus the consensus estimate of $91.59 million.

GUIDANCE:

Harrow Health sees FY2026 revenue of $350-365 million, versus the consensus of $386.4 million.

For earnings history and earnings-related data on Harrow Health (HROW) click here.

You May Also Be Interested In

• DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance
• Nse Said To Seek Up To $55 Billion Valuation In India Ipo - Bloomberg
• CalPrivate Bank names Andra Frazier as chief credit officer